Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1887 1
1914 1
1936 1
1946 1
1955 1
1956 1
1957 1
1959 1
1960 2
1961 6
1962 4
1964 4
1965 2
1966 2
1967 3
1968 3
1969 2
1970 1
1971 1
1972 1
1973 2
1974 3
1975 1
1977 5
1979 2
1980 2
1981 3
1982 3
1983 2
1984 4
1985 6
1986 3
1987 3
1988 6
1989 2
1990 6
1991 5
1992 6
1993 7
1994 11
1995 13
1996 9
1997 6
1998 12
1999 10
2000 10
2001 19
2002 12
2003 13
2004 18
2005 22
2006 29
2007 25
2008 21
2009 25
2010 23
2011 26
2012 28
2013 39
2014 39
2015 55
2016 39
2017 34
2018 34
2019 58
2020 55
2021 63
2022 43
2023 59
2024 38

Text availability

Article attribute

Article type

Publication date

Search Results

902 results

Results by year

Filters applied: . Clear all
Page 1
FSP1 is a glutathione-independent ferroptosis suppressor.
Doll S, Freitas FP, Shah R, Aldrovandi M, da Silva MC, Ingold I, Goya Grocin A, Xavier da Silva TN, Panzilius E, Scheel CH, Mourão A, Buday K, Sato M, Wanninger J, Vignane T, Mohana V, Rehberg M, Flatley A, Schepers A, Kurz A, White D, Sauer M, Sattler M, Tate EW, Schmitz W, Schulze A, O'Donnell V, Proneth B, Popowicz GM, Pratt DA, Angeli JPF, Conrad M. Doll S, et al. Among authors: schulze a. Nature. 2019 Nov;575(7784):693-698. doi: 10.1038/s41586-019-1707-0. Epub 2019 Oct 21. Nature. 2019. PMID: 31634899
LRP8-mediated selenocysteine uptake is a targetable vulnerability in MYCN-amplified neuroblastoma.
Alborzinia H, Chen Z, Yildiz U, Freitas FP, Vogel FCE, Varga JP, Batani J, Bartenhagen C, Schmitz W, Büchel G, Michalke B, Zheng J, Meierjohann S, Girardi E, Espinet E, Flórez AF, Dos Santos AF, Aroua N, Cheytan T, Haenlin J, Schlicker L, Xavier da Silva TN, Przybylla A, Zeisberger P, Superti-Furga G, Eilers M, Conrad M, Fabiano M, Schweizer U, Fischer M, Schulze A, Trumpp A, Friedmann Angeli JP. Alborzinia H, et al. Among authors: schulze a. EMBO Mol Med. 2023 Aug 7;15(8):e18014. doi: 10.15252/emmm.202318014. Epub 2023 Jul 12. EMBO Mol Med. 2023. PMID: 37435859 Free PMC article.
Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test.
Lionel AC, Costain G, Monfared N, Walker S, Reuter MS, Hosseini SM, Thiruvahindrapuram B, Merico D, Jobling R, Nalpathamkalam T, Pellecchia G, Sung WWL, Wang Z, Bikangaga P, Boelman C, Carter MT, Cordeiro D, Cytrynbaum C, Dell SD, Dhir P, Dowling JJ, Heon E, Hewson S, Hiraki L, Inbar-Feigenberg M, Klatt R, Kronick J, Laxer RM, Licht C, MacDonald H, Mercimek-Andrews S, Mendoza-Londono R, Piscione T, Schneider R, Schulze A, Silverman E, Siriwardena K, Snead OC, Sondheimer N, Sutherland J, Vincent A, Wasserman JD, Weksberg R, Shuman C, Carew C, Szego MJ, Hayeems RZ, Basran R, Stavropoulos DJ, Ray PN, Bowdin S, Meyn MS, Cohn RD, Scherer SW, Marshall CR. Lionel AC, et al. Among authors: schulze a. Genet Med. 2018 Apr;20(4):435-443. doi: 10.1038/gim.2017.119. Epub 2017 Aug 3. Genet Med. 2018. PMID: 28771251 Free PMC article.
The multifaceted roles of fatty acid synthesis in cancer.
Röhrig F, Schulze A. Röhrig F, et al. Among authors: schulze a. Nat Rev Cancer. 2016 Nov;16(11):732-749. doi: 10.1038/nrc.2016.89. Epub 2016 Sep 23. Nat Rev Cancer. 2016. PMID: 27658529 Review.
Hydropersulfides inhibit lipid peroxidation and ferroptosis by scavenging radicals.
Barayeu U, Schilling D, Eid M, Xavier da Silva TN, Schlicker L, Mitreska N, Zapp C, Gräter F, Miller AK, Kappl R, Schulze A, Friedmann Angeli JP, Dick TP. Barayeu U, et al. Among authors: schulze a. Nat Chem Biol. 2023 Jan;19(1):28-37. doi: 10.1038/s41589-022-01145-w. Epub 2022 Sep 15. Nat Chem Biol. 2023. PMID: 36109647 Free PMC article.
Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress.
Schug ZT, Peck B, Jones DT, Zhang Q, Grosskurth S, Alam IS, Goodwin LM, Smethurst E, Mason S, Blyth K, McGarry L, James D, Shanks E, Kalna G, Saunders RE, Jiang M, Howell M, Lassailly F, Thin MZ, Spencer-Dene B, Stamp G, van den Broek NJ, Mackay G, Bulusu V, Kamphorst JJ, Tardito S, Strachan D, Harris AL, Aboagye EO, Critchlow SE, Wakelam MJ, Schulze A, Gottlieb E. Schug ZT, et al. Among authors: schulze a. Cancer Cell. 2015 Jan 12;27(1):57-71. doi: 10.1016/j.ccell.2014.12.002. Cancer Cell. 2015. PMID: 25584894 Free PMC article.
USP28 controls SREBP2 and the mevalonate pathway to drive tumour growth in squamous cancer.
Maier CR, Hartmann O, Prieto-Garcia C, Al-Shami KM, Schlicker L, Vogel FCE, Haid S, Klann K, Buck V, Münch C, Schmitz W, Einig E, Krenz B, Calzado MA, Eilers M, Popov N, Rosenfeldt MT, Diefenbacher ME, Schulze A. Maier CR, et al. Among authors: schulze a. Cell Death Differ. 2023 Jul;30(7):1710-1725. doi: 10.1038/s41418-023-01173-6. Epub 2023 May 18. Cell Death Differ. 2023. PMID: 37202505 Free PMC article.
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.
Lanzetta P, Korobelnik JF, Heier JS, Leal S, Holz FG, Clark WL, Eichenbaum D, Iida T, Xiaodong S, Berliner AJ, Schulze A, Schmelter T, Schmidt-Ott U, Zhang X, Vitti R, Chu KW, Reed K, Rao R, Bhore R, Cheng Y, Sun W, Hirshberg B, Yancopoulos GD, Wong TY; PULSAR Investigators. Lanzetta P, et al. Among authors: schulze a. Lancet. 2024 Mar 23;403(10432):1141-1152. doi: 10.1016/S0140-6736(24)00063-1. Epub 2024 Mar 7. Lancet. 2024. PMID: 38461841 Clinical Trial.
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.
Brown DM, Boyer DS, Do DV, Wykoff CC, Sakamoto T, Win P, Joshi S, Salehi-Had H, Seres A, Berliner AJ, Leal S, Vitti R, Chu KW, Reed K, Rao R, Cheng Y, Sun W, Voronca D, Bhore R, Schmidt-Ott U, Schmelter T, Schulze A, Zhang X, Hirshberg B, Yancopoulos GD, Sivaprasad S; PHOTON Investigators. Brown DM, et al. Among authors: schulze a. Lancet. 2024 Mar 23;403(10432):1153-1163. doi: 10.1016/S0140-6736(23)02577-1. Epub 2024 Mar 7. Lancet. 2024. PMID: 38461843 Clinical Trial.
902 results